| Literature DB >> 34250323 |
Neil J Rowan1,2, Elaine Meade3, Mary Garvey3.
Abstract
The emergence of severe acute respiratory disease (SARS-CoV-2) variants that causes coronavirus disease (COVID-19) is of global concern. SARS-Cov-2 variants of concern (VOC) exhibiting greater transmissibility, and potentially increased risk of hospitalization, severity and mortality, are attributed to molecular mutations in outer viral surface spike proteins. Thus, there is a reliance on using appropriate counter-disease measures including non-pharmaceutical interventions and vaccination. Best evidence suggests that use of frontline biocides effectively inactivate coronavirus similarly, including VOC, such as 202012/01, 501Y.V2 and P.1 that have rapidly replaced the wild-type variant in the United Kingdom, South Africa and Brazil, respectively. However, this review highlights that efficacy of VOC-disinfection will depend on type of biocide and parameters governing activity. VOC are likely to be similar in size to the wild-type strain, thus implying that existing guidelines for use and re-use of face masks post disinfection remain relevant. Monitoring to avoid injudicious use of biocides during COVID-19 era is required as prolonged and excessive biocide usage may negatively impact our receiving environments; thus, highlighting the potential for alternative more environmental-friendly sustainable biocide solutions. Traditional biocides may promote cross-antimicrobial resistance (AMR) to antibiotics in problematical bacteria. Existing filtration efficacy of face masks is likely to perform similarly for VOC due to similar viral size; however, advances in face mask manufacturing by way incorporating new anti-viral materials will potentially enhance their design and functionality for existing and potentially future pandemics.Entities:
Keywords: COVID-19; PPE; SAR-Cov-2 variants; biocides; disinfection; environment; healthcare
Year: 2021 PMID: 34250323 PMCID: PMC8254398 DOI: 10.1016/j.coesh.2021.100290
Source DB: PubMed Journal: Curr Opin Environ Sci Health ISSN: 2468-5844
Figure 1Structural components of SARS-COV-2 (left) and effective biocidal agents known to deactivate the virus (right).
Figure 2Use of chemical biocides and other disinfectants to break cycle of COVID-19 disease.
Factors governing anti-viral efficacy of biocides.
| Factors | Comments | Relevance and implication for usage in practice |
|---|---|---|
| Concentration | Understand the effect of dilution upon activity — concentration must be ‘cidal’ to viruses | Appropriate staff training |
| Contact time | Length of exposure can often enhance biocidal efficacy | Appropriate staff training |
| Organic load | Diminish the activity of biocide and protect other contaminating bacteria of concern | Understand physicochemical factors governing biocidal action |
| Formulation | Influences inactivation performance against coronaviruses and intended surface or application for treatment | Understand nation of active agent and impact on intended contact material |
| Temperature | Increased activity against viruses can be achieved with higher temperatures and relevant for some devices (e.g. endoscopes) | Appropriate staff training |
| pH | Affects biocide (stability and ionization) and affects growth of co-infective microorganisms | Less relevant for healthcare environment |
| Presence of biofilm | Provides protective menstrua or environment that can be found on equipment and in certain surfaces | Combine physical cleaning along with chemical action |
| Viral load | The greater the population number of viruses present the more difficult it can be to disinfect | Biocides often used in excess at high level concentration — SARS-CoV appear sensitive to low and moderate levels |
Factors listed in order of importance – adapted from the study by Michie, West, and Harvey [24].
Synopsis of key information on SARS-CoV-2 variants of concern, as reported by World Health Organization on 23rd March, 2021.
| Emerging information | Variant of concern (VOC) | ||
|---|---|---|---|
| Next strain clade | 20I/501Y.V1 | 20H/501Y.V2 | 20J/501Y.V3 |
| PANGO lineage | B.1.1.7 | B.1.351 | B.1.1.28.1 (alias P.10 |
| Alternate name | VOC 20201/01 | VOC 202012/02 | |
| First detected | United Kingdom | South Africa | Brazil |
| First appearance | 20 September, 2020 | Early August, 2020 | December 2020 |
| Key spike mutations | H69/V70 deletion; Y144 deletion; N501Y, A5700, P681H | L242/A243/L244 deletion; K417N E484K, N501Y | N417T, E484K; N501Y |
| Key mutation in common | 5106/G107/F108 deletion in Non-Structural Protein 6 (NSP6) | ||
| Transmissibility | Increased (36–75%), increased secondary attack rate (10–13%) | Increased (1.50 (95% CI: 1.20–2.13) times more transmissible than previously circulating variant | Increased, more transmissible than previous circulating variants |
| Severity | Possible increased risk of hospitalization, severity and mortality | Possible increased risk in hospital mortality by 20% | Under investigation, limited impact |
| Neutralization capacity | Slight reduction, but overall neutralising titres still remained above levels expected to confer protection | Decreased, suggesting potential increased risk of infection. | Decreased reinfections reported |
| Potential Impacts on vaccines | No significant impact on post-vaccine neutralization by Moderna, Pfizer-BioNTech, Oxford-AstraZeneca, Novavax No significant change in prevention of disease by Oxford-AstraZeneca, Novavax, and Pfizer-BioNTech Evidence for prevention of infection evidence limited — reduced effect reported for Oxford-AstraZeneca | Post-vaccine neutralization reductions range from minimal to moderate for Moderna and Pfizer; however, there is also some evidence of more substantial reductions Substantial reductions found for Oxford-AstraZeneca products There is no evidence to inform vaccine impact on asymptomatic infection by 501Y.V2 | Limited to modest reduction in post-vaccine neutralization by Oxford-Astrazeneca, Moderna, and Pfizer-BioNTech vaccines. Preliminary suggestion of loss of neutralization following vaccination with Sinovac |
| Countries reporting new cases (newly reported in last week) | 125 (7) | 73 (11) | 41 (3) |
Adapted from WHO [ ]; note, consult this reference report for more detailed information on emerging information on key VOC.
General properties, strengths and limitations of frontline chemical biocides against coronaviruses.
| Biocide type and active igredient | Mechanism of virucidal Action | General usage | Limitations | Strengths |
|---|---|---|---|---|
| Disrupts cell envelope, coagulates and denatures proteins. Isopropyl alcohol is lipophilic disrupting lipid membrane. | Skin antisepsis (ca 70% v/v) Small equipment disinfection, for example, thermometers, critical tools, non-invasive probes | Not sporicidal | No-staining, low toxicity, mild pleasant odour | |
| Mostly disrupt by solvating or disrupting cell envelope — cationic ammonium groups with hydrophilic heads | Fomites (200 ppm), | Require warmer temperature and longer periods for achieving MEC | Nontoxic, colourless and odourless — retain activity in hard water, high tolerance to organic matter | |
| Oxidation of cell envelope | Household bleach — dissolves in water to form hypochlorous acid — used in clinical area for fomites, non-critical surfaces where there is blood spillage or vomit | Sensitive to presence of organic matter and porous material — can range from <1000 pm to 10,000 ppm depending on organic material — cleaning step and ventilation needed | Fast acting at low concentrations — inactivates envelope and non-envelope viruses | |
| Hydroxyl free radicals cleave or crosslink biomolecules including proteins, nucleic acids, an lipids | Skin antisepsis (0.125% v/v); contact surfaces (35% v/v) | Limited information. Concentration of 0.5% effective against enveloped and non-envelop viruses. | Decomposes to form water and oxygen — effective against SARS-CoV-2 and surrogates — can be used on stainless steel | |
| Possibly blocking receptor for viral binding. Iodine can inhibit viral enzymes (neuraminidase) essential for viral release from host | PVP-1 (0.23%) used for rapid skin, oral cavity, nasal disinfection. Povidone iodine used at 7.5–10% pre-operative skin disinfection, antiseptic hand washes, scrubs, ointments | Can be cytotoxic and cause skin irritancy — Is an iodophor is mixture of iodine and carrier polymerpolyvinl pyrrolidone — not suitable for use with silicone products | PVP-1 water soluble, stains can be removed by washing. Substitute or used in combination with for alcohol-based disinfection products. | |
| Chemically alkylating the amino and sulfhydryl groups of proteins and amino groups of nucleic acid bases | High level broad spectrum virucidal disinfection — vaccine production — decontaminates of surgical equipment, endoscopes, dialysers. | High reactivity, hazardous to health — irritant. Apart from OPE, more reactive at alkaline conditions. Pungent odour <1 ppm, monitoring. | Rubber, plastics, lensed instruments are tolerant. OPA chemically stable over pH 3–9, non-irritant, stains skin wear PPE. |
QAC – Quaternary ammonium compounds; BZK - benzalkonium chloride; mon; MBAT - biz(tri-methyl ammonium methylene chloride)-alkaly (C9-15) toluene; DDA – didecyldimethyl ammonium chloride; OPA – Ortho-phthalaldehyde or 1,2-dicarboxybenzaldehyde.
MEC –lowest concentration of biocide that reduces virus titre by 99.9% or greater compared to control reactions. Adapted from Lin [ ], Dev Kumar [ ].
Use of different disinfection approaches for inactivating SARS-CoV-2 and its’ surrogate indicators.
| Disinfectant | Parameters | SARS-CoV-2 & Surrogate species | Reduction | |
|---|---|---|---|---|
| Chemical | Ethanol | 60–70%, 1 min, hard surfaces, ceramic and porcelain tiles -carrier test. | hCoV (HCoV-229e) | 3 - 4 log, TCID50 assay [ |
| H2O2 | 0.5%, 15 min, surface carrier test | SARS-CoV-2 | 6 log plaque assay using Vero E6 cells [ | |
| QAC – BAC | 0.04% w/v, 1 min, steel surface. quantitative carrier test | Parainfluenzavirus type 3 (HPIV-3) and human coronavirus 229-E (HOV-229E) | 3 log | |
| Sodium hypochlorite | 0.1%, 1 min, suspension test. | SARS-CoV-2 | 4 log [ | |
| IPA | 70–90%, 30 s | SARS-CoV-1 | 4 log, | |
| Acetic acid | 6%, 5 min, aqueous suspension test. | SARS-CoV-2 (Hu/DP/Kng/19–020 strain) | 4 log | |
| Glutaraldehyde | 0.5%, 2 min, suspension test | SARS-CoV | 3 log | |
| Formaldehyde | 0.7–1%, 2 min, suspension test | |||
| Povidone iodine | 1–2.5%, 15 s, suspension testing of oral mouth wash | SARS-CoV-2, USA-WA1/2020 strain | 4 log | |
| Technologies | Steam sterilisation | 121 °C, 5 min, medical masks, N95 respirators | Avian coronavirus (H120) | 2 log |
| Heat | 56 °C, 30 min, 65 °C, 15 min, 98 °C 2 min, suspension test. | SARS-CoV-2 | 5 log | |
| Deep UV LED | 265, 280, and 300 nm, 20 s, hard surfaces, carrier test | SARS-CoV-2 | 3.3 log | |
| Simulated sunlight | 60 min on hard surfaces, carrier test on surface dried droplets. | SARS-CoV-2 USA-WA1/2020 | 4 log. TCID50 assay using Vero cells (ATCC CCL-81) [ | |
| UVC | 254 nm, 4–9 s, wet and dried droplets | SARS-CoV-2 | 3 log | |
| Ozone | 30 ppmv, 40 min100 ppmv, 30 min, 1000 ppmv, 20 min on surfaces, carrier test. | hCoV 229E (HuCoV-229E) | 95% reduction (1 log) HEK-293 cells and imaging using IncuCyte ZOOM system [ | |
| Vapourised H2O2 | 0.5%, 60 s, surface of stainless steel disks, carrier test. | feline calicivirus, human adenovirus type 1, avian and swine influenza virus | 4 log | |
| Chlorine dioxide gas (ClO2) | 30–300 ppm, 25 °C to 30 °C, 1.5–3 h, in vivo. | avian infectious bronchitis coronavirus | infected chick embryos as models [ | |
| Gamma radiation (cobalt-60) | 1–5 MRads, suspension test. | arenavirus, bunyavirus, coronavirus, filovirus, flavivirus, orthomyxovirus, paramyxovirus | 6 log | |
TCID50 assay - Tissue Culture Infectious Dose assay, QAC quaternary ammonia compound, BAC benzalkonium chloride, DDAC didecyl dimethyl ammonium chloride.